Want to see AU:IIQ full AI Analyst Report?
Top Page
Inoviq Ltd
(Sydney:IIQ)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.18
▼(-55.25% Downside)
Action:Upgraded
Date:08/29/26
The score is primarily constrained by weak financial performance—sharp revenue decline, sustained losses, and continued cash burn—partially offset by a low-debt balance sheet. Technicals also weigh on the score as the stock trades below all key moving averages with negative MACD. Valuation is difficult to justify from earnings due to a negative P/E and no dividend yield data.
Positive Factors
Low Leverage
Very low leverage limits interest and refinancing pressure, preserving financial flexibility while INOVIQ funds product development and seeks commercial traction. This provides a stronger solvency base than a similarly loss-making business carrying substantial debt.
Negative Factors
Revenue Contraction
The sharp revenue decline shows that commercial scale and demand remain fragile. A smaller revenue base makes fixed research, development and corporate costs harder to absorb, limiting operating leverage and weakening confidence in near-term business durability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage limits interest and refinancing pressure, preserving financial flexibility while INOVIQ funds product development and seeks commercial traction. This provides a stronger solvency base than a similarly loss-making business carrying substantial debt.
Read all positive factors
Inoviq Ltd (IIQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$23.93M
Dividend YieldN/A
Average Volume (3M)116.57K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue Growth-21.10%
EPS Growth8.03%
CountryAU
Employees15
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,775,450
10 Day Avg. Volume178,831
30 Day Avg. Volume116,572
Financial Highlights & Ratios
PEG Ratio1.11
Price to Book (P/B)3.81
Price to Sales (P/S)166.47
P/FCF Ratio-10.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Inoviq Ltd Business Overview & Revenue Model
Company Description
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current p...
How the Company Makes Money
INOVIQ’s revenue model is based on commercialising its diagnostic and bioscience offerings through product and service sales, and through collaborations where its technology is used by third parties. Key revenue streams include: (1) Sale of diagno...
Inoviq Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
27
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 432.05K | 1.82M | 535.12K | 398.19K | 276.75K |
| Gross Profit | -974.92K | -1.56M | 454.11K | -1.04M | -1.88M |
| EBITDA | -8.34M | -6.16M | -6.34M | -9.32M | -19.39M |
| Net Income | -7.51M | -6.93M | -6.55M | -8.97M | -18.20M |
Balance Sheet | |||||
| Total Assets | 20.45M | 18.46M | 21.71M | 21.51M | 30.78M |
| Cash, Cash Equivalents and Short-Term Investments | 9.35M | 6.52M | 9.23M | 7.81M | 15.39M |
| Total Debt | 289.39K | 376.19K | 776.54K | 730.71K | 998.69K |
| Total Liabilities | 1.56M | 1.74M | 1.72M | 1.89M | 2.49M |
| Stockholders Equity | 18.89M | 16.71M | 19.99M | 19.62M | 28.29M |
Cash Flow | |||||
| Free Cash Flow | -6.55M | -4.77M | -4.50M | -7.32M | -6.47M |
| Operating Cash Flow | -6.38M | -4.66M | -4.32M | -7.02M | -6.06M |
| Investing Cash Flow | -168.33K | -104.00K | -174.34K | -292.27K | -411.90K |
| Financing Cash Flow | 9.39M | 2.05M | 5.91M | -267.98K | 16.87M |
Inoviq Ltd Technical Analysis
Negative
0.40
Price Trends
0.20
Negative
0.28
Negative
0.31
Negative
Market Momentum
>-0.01
Negative
35.94
Neutral
43.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IIQ, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.20, and above the 200-day MA of 0.31, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 35.94 is Neutral, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IIQ.
Inoviq Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$17.72M | -1.31 | -35.10% | ― | -9.10% | 31.75% | |
45 Neutral | AU$29.85M | -4.92 | -205.17% | ― | 239.64% | -37.21% | |
44 Neutral | AU$23.93M | -3.14 | -36.48% | ― | -21.10% | 8.03% | |
43 Neutral | AU$23.96M | -3.78 | -881.94% | ― | 743.51% | -1.52% | |
42 Neutral | AU$6.41M | -0.71 | 165.88% | ― | -100.00% | -3.67% |
* Healthcare Sector Average
AU:IIQ
Inoviq Ltd
0.18
-0.21
-53.85%
AU:BDX
BCAL Diagnostics Limited
0.08
0.02
26.67%
AU:RHY
Rhythm Biosciences Ltd.
0.09
<0.01
2.35%
AU:GSS
Genetic Signatures Ltd.
0.08
-0.20
-71.07%
AU:IBX
Imagion Biosystems Ltd.
0.01
-0.02
-67.74%
Inoviq Ltd Corporate Events
Inoviq Files Appendix 4G, Confirms ASX Governance Compliance
Aug 27, 2026
Inoviq Limited has lodged its Appendix 4G key to corporate governance disclosures with the ASX for the financial year ended 30 June 2026, confirming that its corporate governance statement is available on its website and current as of 27 August 20...
INOVIQ widens annual loss as revenue falls but asset backing improves
Aug 27, 2026
INOVIQ Limited reported a 21.1% decline in revenue from ordinary operations to $432,047 for the year ended 30 June 2026, while other income rose 29.9% to $2.18 million. The company posted a net loss after tax of $7.51 million, an 8.3% increase on ...
Inoviq updates director interest as listed options expire
Jul 15, 2026
Inoviq Limited has reported a change in the holdings of director Peter Gunzburg, providing an updated account of his indirect interests in the company’s ordinary shares through several related entities. The notice reflects standard governanc...
INOVIQ outlines investor risks in EXO-OC cancer test briefing
Jul 13, 2026
INOVIQ Ltd has released an investor presentation on its EXO-OC test, positioning the assay within its broader push into next-generation cancer diagnostics and therapeutics. The document primarily serves as a high-level briefing for investors, outl...
INOVIQ Advances Exosome Cancer Programs Despite Setback in Ovarian Test Study
Jul 12, 2026
INOVIQ has reported a cash balance of A$9.353m at 30 June 2026 and provided a quarterly update centred on its EXO-OC ovarian cancer blood test and CAR-exosome therapy program. The company remains focused on commercialising EXO-OC initially as a U....
INOVIQ to Brief Investors After Setback in EXO-OC Ovarian Cancer Study
Jul 7, 2026
INOVIQ Ltd will host an online investor briefing to discuss the disappointing outcome of a retrospective clinical study of its EXO-OC ovarian cancer test, outlining key findings, technical review steps and plans to refine the test and its algorith...
INOVIQ boosts EXO-OC accuracy but halts flawed ovarian cancer study
Jul 1, 2026
INOVIQ has enhanced the algorithm underpinning its EXO-OC ovarian cancer blood test, reporting improved diagnostic performance with over 92% sensitivity for both early-stage and all-stage disease at high specificity on its initial 500-sample datas...
Inoviq Seeks Trading Halt Ahead of Key EXO-OC Clinical Study Results
Jun 28, 2026
Inoviq Ltd, an ASX-listed medical diagnostics company focused on oncology-related blood tests such as its EXO-OC assay, is progressing clinical validation of its product pipeline to strengthen its position in the biotechnology sector. The company&...
Inoviq Options Lapse Removes 1.1 Million Potential Shares
Jun 26, 2026
Inoviq Ltd has notified the market that 1,100,000 options, classified under the ASX security code IIQAE and expiring on various dates at various prices, have lapsed. The options ceased due to the non-satisfaction or incapacity of conditions attach...
INOVIQ posts strong ovarian cancer data for off-the-shelf CAR-exosome therapy
Jun 24, 2026
INOVIQ reported positive in vitro proof-of-concept data showing its CAR-exosome platform achieved rapid tumour-killing in multiple ovarian cancer cell lines, eliminating up to 90% of cells within 48 hours when targeting CA125 and over 80% when tar...
Inoviq links share price jump to research note as key EXO-OC study nears milestone
Jun 17, 2026
Inoviq has responded to an ASX price query after its shares rose from A$0.295 to A$0.365 in a single day, stating it is not aware of any undisclosed information that could explain the trading activity. The company instead pointed to a third-party ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.